Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide-specific Vaccination in HLA-A*02 Positive Prostate Carcinoma Patients With Biochemical Recurrence
NCT02452307Phase 2Unknown
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2004
- Primary completion
- Oct 2017
01
Overview
Phase 2, randomised trial in prostate cancer (PCa) (5 arms), sponsored by University Hospital Tübingen. Primary endpoint: Change from Baseline in Immune Response at day 70. Status: unknown.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02452307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452307.